logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Ravulizumab for paroxysmal nocturnal haemoglobinuria in paediatrics

< Back

Ravulizumab for paroxysmal nocturnal haemoglobinuria in paediatrics

Drugs

January 2021


Ravulizumab is in clinical development for the treatment of paediatric patients with paroxysmal nocturnal hemoglobinuria (PNH). PNH is a rare blood condition in which red blood cells are attacked by the body’s immune system. PNH is a chronic condition that is associated with complications that can be severely debilitating and life-threatening including abdominal pain, kidney problems, fatigue, shortness of breath, bleeding and blood clots, dysphagia, organ damage and premature mortality.
Ravulizumab, administered intravenously, works by attaching to the complement component 5 (C5) protein, which is part of the complement system (a component of the immune system). By attaching to the C5 protein, ravulizumab blocks its effect and thereby reduces the destruction of red blood cells. If licensed, ravulizumab will provide a treatment option for paediatric patients with PNH.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Get Alerts